ADAR1 Capital Management’s Spruce Biosciences SPRB Stock Holding History

ADAR1 Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.66M	Buy	67,717 +9,117	+16%	+$510K	0.17%	116
2026 Q1	$3.83M	Buy	58,600 +600	+1%	+$41.4K	0.23%	91
2025 Q4	$5.05M	Buy	+58,000	New	+$6.21M	0.37%	59
2025 Q2	–	Sell	-5,383	Closed	-$117K	–	245
2025 Q1	$117K	Hold	5,383	–	–	0.02%	159
2024 Q4	$170K	Hold	5,383	–	–	0.03%	164
2024 Q3	$192K	Buy	5,383 +647	+14%	+$23.7K	0.03%	164
2024 Q2	$184K	Sell	4,736 -134	-3%	-$7.18K	0.03%	144
2024 Q1	$287K	Buy	+4,870	New	+$1.24M	0.07%	105

Other funds holding SPRB

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

ADAR1 Capital Management's SPRB Position: Q2 2026 in Review

ADAR1 Capital Management increased its Spruce Biosciences (SPRB) stake by 16% in Q2 2026, buying an estimated $510K and bringing the position to 67,717 shares worth $3.66M. The position accounts for 0.17% of the portfolio, ranked #116.

ADAR1 Capital Management first reported a position in SPRB in Q1 2024 and has held it in 8 quarters since. The position peaked at $5.05M in Q4 2025. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

ADAR1 Capital Management held 67,717 shares of Spruce Biosciences worth $3.66M as of Q2 2026.
ADAR1 Capital Management bought 9,117 Spruce Biosciences shares in Q2 2026, an estimated $510K.
Spruce Biosciences made up 0.17% of ADAR1 Capital Management's portfolio in Q2 2026, its #116 holding.
ADAR1 Capital Management first reported a position in Spruce Biosciences in Q1 2024 and has held it in 8 quarters since.
ADAR1 Capital Management's Spruce Biosciences position peaked at $5.05M in Q4 2025.
57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.